Most biotechs that get bought for a nice premium are pre commercial or commercial but not at break even yet. Heck sgen at 42B is not profitable You’re really a neophyte in the biotech space apparently
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.